<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81867">
  <stage>Registered</stage>
  <submitdate>19/02/2007</submitdate>
  <approvaldate>20/02/2007</approvaldate>
  <actrnumber>ACTRN12607000136404</actrnumber>
  <trial_identification>
    <studytitle>The impact on cognitive function and dementia of diagnostic and treatment alternatives for coronary artery disease. The Dementia In Response to Endovascular and Cardiac surgical Therapies (DIRECT) Study.</studytitle>
    <scientifictitle>This prospective observational study will document the preoperative neuropsychological status of patients presenting for coronary angiography (CA) and relate this to cognitive outcomes, including the rate of conversion to dementia, over the succeeding two years</scientifictitle>
    <utrn />
    <trialacronym>Dementia In Response to Endovascular and Cardiac surgical Therapies (DIRECT) Study.</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Patients presenting for coronary angiography (CA).</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To test whether the onset of dementia during the two years following coronary intervention(s) is related to Mild Cognitive Impairment (MCI) prior to CA and the occurrence of Post Procedural Cognitive Dysfunction (PPCD). Patients will complete a battery of conventional and computerised neuropsychological tests preoperatively. The conventional test battery is a set of eight paper and pencil tests (eg. trail making tests A and B, digit symbol test, Rey Auditory Verbal Learning test) and the computerised battery is a version of CogstateÂ®. The tests take about one hour to complete. They will then complete the computerised test battery at 6 days, 3 months, 12 months and 24 months post intervention to identify changes in cognitive function.  Quality of Life (QoL), mood, Activities of Daily Living (ADL) and Clinical Dementia Rating (CDR) will be assessed preoperatively and at 12 months and 24 months.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of dementia.</outcome>
      <timepoint>12 and 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of PPCD</outcome>
      <timepoint>6 days, 3, 12 &amp;  24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Scheduled for elective CA who do not have neurological (as opposed to neuropsychological) deficit or any contraindication to undergoing neuropsychological testing, and have given informed consent. The patients must reside in accessible proximity to the hospital to enable investigators to administer neuropsychological testing at home.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>i.Pre-existing neurological or clinically evident neurovascular disease (e.g. TIA, stroke);ii.Dementia: a score less than 26 on the Mini Mental State Examination (MMSE) or CDR &gt; 1;iii.Anticipated difficulty with neuropsychological assessment such as: English not being the prime language; blindness; deafness;iv.Geographical remoteness or medical co-morbidity that may lead to complications and loss to follow-up.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>510</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof David Scott</primarysponsorname>
    <primarysponsoraddress>St. Vincent's Hospital, PO BOX 2900, Fitzroy, Melbourne, Victoria 3065</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council project grant # 447709</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof Brendan Silbert</sponsorname>
      <sponsoraddress>St. Vincent's Hospital, PO BOX 2900, Fitzroy, Melbourne, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Michael Yii</sponsorname>
      <sponsoraddress>St. Vincent's Hospital, PO BOX 2900, Fitzroy, Melbourne, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof David Ames</sponsorname>
      <sponsoraddress>St. George's, St. Vincent's Health, PO BOX 2900, Fitzroy, Melbourne, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof Andrew MacIsaac</sponsorname>
      <sponsoraddress>St. Vincent's Hospital, PO BOX 2900, Fitzroy, Melbourne, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Konrad Jamrozik</sponsorname>
      <sponsoraddress>c/o St. Vincent's Hospital, PO BOX 2900, Fitzroy, Melbourne, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Paul Maruff</sponsorname>
      <sponsoraddress>Neurosciences, University of Melbourne, Parkville, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Individuals with symptomatic CAD probably constitute a population at high risk for accelerated decline in cognitive function, because of the overlap between Alzheimers disease, vascular dementia and the risk factors for both. Appropriate clinical decision-making for these patients depends on the accurate understanding of the prevalence of prodromal conditions such as MCI, the incidence of PPCD and how they affect the rate of conversion to dementia in these patients.</summary>
    <trialwebsite>www.cognition.org.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. Vincent's Hospital</ethicname>
      <ethicaddress>Melbourne </ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St. Vincent's &amp; Mercy Private Hospital</ethicname>
      <ethicaddress>Melbourne </ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor David Scott</name>
      <address>Department of Anaesthesia
St. Vincents Hospital
P.O. Box 2900
Fitzroy, Melbourne VIC 3065</address>
      <phone>+61 3 92884253</phone>
      <fax>+61 3 92884255</fax>
      <email>david.scott@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms. Lis Evered</name>
      <address>Department of Anaesthesia
St. Vincents Hospital
P.O. Box 2900
Fitzroy, Melbourne VIC 3065</address>
      <phone>+61 3 92882251</phone>
      <fax>+61 3 92884255</fax>
      <email>lis.evered@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>